Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who are willing and able to sign a written consent form before any screening steps begin
• People whose overall health and ability to carry out daily activities meets a certain level (a score of 2 or lower on a standard medical scale, where 0 means fully active and 5 means completely disabled — confirm with trial site)
• People who have been diagnosed with multiple myeloma that is causing symptoms, and whose disease has come back or stopped responding to treatment, and who have already received at least 4 previous rounds of treatment — including at least one treatment from each of these three groups: proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies (prior treatment targeting a protein called BCMA is also permitted)
• People whose treating doctor determines they are eligible to receive one of three specific cancer medicines — teclistamab, elranatamab, or talquetamab — at the doses listed on the approved label
• People who previously had a serious immune reaction (called CRS or ICANS) from a bispecific antibody treatment, but where that reaction has fully resolved before starting the study drug
• People who have a measurable level of disease, shown by specific protein or light chain levels in the blood or urine, or a measurable tumour outside the bone marrow (confirm details with trial site)
• People whose liver is working well enough, based on blood tests taken within 28 days before starting treatment (specific values will be checked by the trial site)
• People whose kidneys are working well enough, based on a calculated measure of kidney filtering ability of at least 15 mL/min, using a blood test taken within 28 days before starting treatment
• People whose blood cell counts meet minimum levels, based on tests taken within 7 days before starting treatment — including white blood cells, red blood cells, and platelets (people who use growth factor support or have received transfusions may still be eligible — confirm with trial site)
• People who could become pregnant and have a negative pregnancy blood test at the screening stage
• People who could become pregnant or could father a child, and who agree to use highly effective contraception throughout the study and for 5 months after the last dose of the study treatment
• People who agree not to donate eggs (if female) or sperm (if male) during the study and for up to 90 days after the last dose of the study drug selinexor

Who may not be able to join:

• People whose myeloma did not respond to selinexor or a similar type of drug (called a SINE compound) when they previously received it — note: people who received selinexor but whose disease did respond may still be considered
• People who have another medical condition that is not well controlled and is likely to interfere with study procedures, such as uncontrolled high blood pressure, uncontrolled diabetes, or an active serious infection
• People who have an active, uncontrolled infection requiring medical or surgical treatment within one week before the first dose — note: people on preventive antibiotics or with a controlled infection may still be considered
• People who are currently pregnant or breastfeeding
• People who have unstable heart or cardiovascular problems, such as chest pain from reduced blood flow, serious uncontrolled heart rhythm problems, moderate to severe heart failure, a heart pumping strength below 40%, or a heart attack within the past 3 months (certain mild or asymptomatic heart rhythm findings may still be eligible — confirm with trial site)
• People with hepatitis B, hepatitis C, or HIV may not be eligible unless certain conditions are met, such as being on antiviral therapy with a low viral load (for hepatitis B), having been successfully treated and cleared of hepatitis C, or having a sufficient immune cell count and no recent serious infections (for HIV) — confirm with trial site
• People who still have any level of a serious immune reaction (CRS or ICANS) at around 5 days after their first full dose of bispecific antibody treatment
• People who have digestive or stomach problems that would make it difficult to swallow tablets or absorb the study medicine
• People who are unwilling or unable to take recommended medicines to manage nausea or loss of appetite as part of their supportive care
• People who have a mental health condition, medical condition, or other circumstance that, in the investigator's judgement, would interfere with treatment, the ability to follow the study requirements, or the ability to give informed consent
• People who cannot take certain other medicines that are required alongside the study treatment
• People who are unwilling or unable to follow the requirements of the study protocol

Important: Always verify eligibility with the trial site directly before applying.